Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 May;71(5):1025–1028. doi: 10.1038/bjc.1995.197

Assay of matrix metalloproteases types 8 and 9 by ELISA in human breast cancer.

M J Duffy 1, J Blaser 1, C Duggan 1, E McDermott 1, N O'Higgins 1, J J Fennelly 1, H Tschesche 1
PMCID: PMC2033810  PMID: 7734294

Abstract

Results from model tumour systems suggest that either increased levels of certain metalloproteases (MMPs) or decreased levels of their inhibitors correlate with metastatic potential. In this study, levels of two MMPs, i.e. MMP-8 and -9, and their inhibitor tissue inhibitor of metalloprotease type 1 (TIMP-1) were measured by enzyme-linked immunosorbent assay in human breast tumours. Levels of MMP-8 and -9 correlated significantly with each other, but neither MMP correlated with urokinase plasminogen activator. Levels of both MMP-8 and -9 were also significantly related to levels of TIMP-1. In contrast, neither MMP correlated with plasminogen activator inhibitor. No relationship was found between MMP-8, MMP-9 or TIMP-1 and either tumour size or metastasis to axillary nodes. MMP-8 and -9 levels were inversely related to levels of oestrogen receptors. MMP-8 but not MMP-9 levels were also inversely correlated with progesterone receptor levels. It is concluded that the assay for MMP-8 and -9 described here will permit the evaluation of these proteases as prognostic markers in cancer.

Full text

PDF
1025

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alvarez O. A., Carmichael D. F., DeClerck Y. A. Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases. J Natl Cancer Inst. 1990 Apr 4;82(7):589–595. doi: 10.1093/jnci/82.7.589. [DOI] [PubMed] [Google Scholar]
  2. Aznavoorian S., Murphy A. N., Stetler-Stevenson W. G., Liotta L. A. Molecular aspects of tumor cell invasion and metastasis. Cancer. 1993 Feb 15;71(4):1368–1383. doi: 10.1002/1097-0142(19930215)71:4<1368::aid-cncr2820710432>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  3. Bergmann U., Michaelis J., Oberhoff R., Knäuper V., Beckmann R., Tschesche H. Enzyme linked immunosorbent assays (ELISA) for the quantitative determination of human leukocyte collagenase and gelatinase. J Clin Chem Clin Biochem. 1989 Jun;27(6):351–359. doi: 10.1515/cclm.1989.27.6.351. [DOI] [PubMed] [Google Scholar]
  4. Brown P. D., Bloxidge R. E., Anderson E., Howell A. Expression of activated gelatinase in human invasive breast carcinoma. Clin Exp Metastasis. 1993 Mar;11(2):183–189. doi: 10.1007/BF00114976. [DOI] [PubMed] [Google Scholar]
  5. Daidone M. G., Silvestrini R., D'Errico A., Di Fronzo G., Benini E., Mancini A. M., Garbisa S., Liotta L. A., Grigioni W. F. Laminin receptors, collagenase IV and prognosis in node-negative breast cancers. Int J Cancer. 1991 Jun 19;48(4):529–532. doi: 10.1002/ijc.2910480409. [DOI] [PubMed] [Google Scholar]
  6. Davies B., Miles D. W., Happerfield L. C., Naylor M. S., Bobrow L. G., Rubens R. D., Balkwill F. R. Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer. 1993 May;67(5):1126–1131. doi: 10.1038/bjc.1993.207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. DeClerck Y. A., Perez N., Shimada H., Boone T. C., Langley K. E., Taylor S. M. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res. 1992 Feb 1;52(3):701–708. [PubMed] [Google Scholar]
  8. DeClerck Y. A., Yean T. D., Chan D., Shimada H., Langley K. E. Inhibition of tumor invasion of smooth muscle cell layers by recombinant human metalloproteinase inhibitor. Cancer Res. 1991 Apr 15;51(8):2151–2157. [PubMed] [Google Scholar]
  9. Duffy M. J., Brouillet J. P., Reilly D., McDermott E., O'Higgins N., Fennelly J. J., Maudelonde T., Rochefort H. Cathepsin D concentration in breast cancer cytosols: correlation with biochemical, histological, and clinical findings. Clin Chem. 1991 Jan;37(1):101–104. [PubMed] [Google Scholar]
  10. Duffy M. J., O'Grady P., Devaney D., O'Siorain L., Fennelly J. J., Lijnen H. J. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. Cancer. 1988 Aug 1;62(3):531–533. doi: 10.1002/1097-0142(19880801)62:3<531::aid-cncr2820620315>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  11. Duffy M. J., O'Siorain L., Waldron B., Smith C. Estradiol receptors in human breast carcinomas assayed by use of monoclonal antibodies. Clin Chem. 1986 Oct;32(10):1972–1974. [PubMed] [Google Scholar]
  12. Duffy M. J. The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis. 1992 May;10(3):145–155. doi: 10.1007/BF00132746. [DOI] [PubMed] [Google Scholar]
  13. Günther M., Haubeck H. D., van de Leur E., Bläser J., Bender S., Gütgemann I., Fischer D. C., Tschesche H., Greiling H., Heinrich P. C. Transforming growth factor beta 1 regulates tissue inhibitor of metalloproteinases-1 expression in differentiated human articular chondrocytes. Arthritis Rheum. 1994 Mar;37(3):395–405. doi: 10.1002/art.1780370314. [DOI] [PubMed] [Google Scholar]
  14. Hasty K. A., Pourmotabbed T. F., Goldberg G. I., Thompson J. P., Spinella D. G., Stevens R. M., Mainardi C. L. Human neutrophil collagenase. A distinct gene product with homology to other matrix metalloproteinases. J Biol Chem. 1990 Jul 15;265(20):11421–11424. [PubMed] [Google Scholar]
  15. Höyhtyä M., Hujanen E., Turpeenniemi-Hujanen T., Thorgeirsson U., Liotta L. A., Tryggvason K. Modulation of type-IV collagenase activity and invasive behavior of metastatic human melanoma (A2058) cells in vitro by monoclonal antibodies to type-IV collagenase. Int J Cancer. 1990 Aug 15;46(2):282–286. doi: 10.1002/ijc.2910460224. [DOI] [PubMed] [Google Scholar]
  16. Jänicke F., Schmitt M., Pache L., Ulm K., Harbeck N., Höfler H., Graeff H. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat. 1993;24(3):195–208. doi: 10.1007/BF01833260. [DOI] [PubMed] [Google Scholar]
  17. Khokha R., Waterhouse P., Yagel S., Lala P. K., Overall C. M., Norton G., Denhardt D. T. Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells. Science. 1989 Feb 17;243(4893):947–950. doi: 10.1126/science.2465572. [DOI] [PubMed] [Google Scholar]
  18. Monteagudo C., Merino M. J., San-Juan J., Liotta L. A., Stetler-Stevenson W. G. Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue. Am J Pathol. 1990 Mar;136(3):585–592. [PMC free article] [PubMed] [Google Scholar]
  19. Montgomery A. M., De Clerck Y. A., Langley K. E., Reisfeld R. A., Mueller B. M. Melanoma-mediated dissolution of extracellular matrix: contribution of urokinase-dependent and metalloproteinase-dependent proteolytic pathways. Cancer Res. 1993 Feb 1;53(3):693–700. [PubMed] [Google Scholar]
  20. Ossowski L. Invasion of connective tissue by human carcinoma cell lines: requirement for urokinase, urokinase receptor, and interstitial collagenase. Cancer Res. 1992 Dec 15;52(24):6754–6760. [PubMed] [Google Scholar]
  21. Poulsom R., Pignatelli M., Stetler-Stevenson W. G., Liotta L. A., Wright P. A., Jeffery R. E., Longcroft J. M., Rogers L., Stamp G. W. Stromal expression of 72 kda type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am J Pathol. 1992 Aug;141(2):389–396. [PMC free article] [PubMed] [Google Scholar]
  22. Pujol P., Maudelonde T., Daures J. P., Rouanet P., Brouillet J. P., Pujol H., Rochefort H. A prospective study of the prognostic value of cathepsin D levels in breast cancer cytosol. Cancer. 1993 Mar 15;71(6):2006–2012. doi: 10.1002/1097-0142(19930315)71:6<2006::aid-cncr2820710614>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  23. Pyke C., Ralfkiaer E., Huhtala P., Hurskainen T., Danø K., Tryggvason K. Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization. Cancer Res. 1992 Mar 1;52(5):1336–1341. [PubMed] [Google Scholar]
  24. Reilly D., Christensen L., Duch M., Nolan N., Duffy M. J., Andreasen P. A. Type-1 plasminogen activator inhibitor in human breast carcinomas. Int J Cancer. 1992 Jan 21;50(2):208–214. doi: 10.1002/ijc.2910500209. [DOI] [PubMed] [Google Scholar]
  25. Rochefort H. Cathepsin D in breast cancer: a tissue marker associated with metastasis. Eur J Cancer. 1992;28A(11):1780–1783. doi: 10.1016/0959-8049(92)90003-k. [DOI] [PubMed] [Google Scholar]
  26. Stearns M. E., Wang M. Type IV collagenase (M(r) 72,000) expression in human prostate: benign and malignant tissue. Cancer Res. 1993 Feb 15;53(4):878–883. [PubMed] [Google Scholar]
  27. Stetler-Stevenson W. G., Krutzsch H. C., Liotta L. A. Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J Biol Chem. 1989 Oct 15;264(29):17374–17378. [PubMed] [Google Scholar]
  28. Ståhle-Bäckdahl M., Parks W. C. 92-kd gelatinase is actively expressed by eosinophils and stored by neutrophils in squamous cell carcinoma. Am J Pathol. 1993 Apr;142(4):995–1000. [PMC free article] [PubMed] [Google Scholar]
  29. Urbanski S. J., Edwards D. R., Maitland A., Leco K. J., Watson A., Kossakowska A. E. Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas. Br J Cancer. 1992 Dec;66(6):1188–1194. doi: 10.1038/bjc.1992.434. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Wilhelm S. M., Collier I. E., Marmer B. L., Eisen A. Z., Grant G. A., Goldberg G. I. SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J Biol Chem. 1989 Oct 15;264(29):17213–17221. [PubMed] [Google Scholar]
  31. Woessner J. F., Jr Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991 May;5(8):2145–2154. [PubMed] [Google Scholar]
  32. Zucker S., Lysik R. M., Zarrabi M. H., Moll U. M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res. 1993 Jan 1;53(1):140–146. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES